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Abstract The aim of the present experiments was to examine
anticonvulsant activity of new pyrrolidine-2,5-dione and 3-
methylpyrrolidine-2,5-dione derivatives in animal models of
epilepsy. In addition, the possible collateral antinociceptive
activity was assessed. Anticonvulsant activity was investigat-
ed in the electroconvulsive threshold (MEST) test and the
pilocarpine-induced seizure models in mice. Antinociceptive
activity was examined in the hot plate and the formalin tests in
mice. Considering the drug safety evaluation, the Vibrio
harveyi test was used to estimate anti/mutagenic activity. To
determine the plausible mechanism of anticonvulsant action,
for two chosen compounds (12 and 23), in vitro binding as-
says were carried out. All of the tested compounds revealed
significant anticonvulsant activity in the MEST test. Com-
pounds 12 and 23 displayed anticonvulsant effect also in
pilocarpine-induced seizures. Four of the tested compounds
(12, 13, 15, and 24) revealed analgesic activity in the hot plate
test as well as in the first phase of the formalin test, and all of
them were active in the second phase of the formalin test. The
possible mechanism of action of compounds 12 and 23 is the
influence on the neuronal voltage-sensitive sodium and L-type
calcium channels. The obtained results indicate that in the
group of pyrrolidine-2,5-diones, new anticonvulsants with
collateral analgesic properties can be found.
Keywords Anticonvulsant . Antinociceptive .
Mutagenicity and antimutagenicity studies .
Ion channels binding . Pyrrolidine-2,5-dione . Lacosamide
Introduction
Epilepsy is a common neurological disorder throughout the
world which is characterized by recurrent unprovoked sei-
zures. On the one hand, preclinical research has allowed the
discovery of numerous efficacious drugs. On the other hand,
introduction of new drugs into clinical practice has not essen-
tially altered the fact that seizures in 30% of epileptics are still
improperly controlled. Therefore, there is an urgent necessity
for new drugs effective against drug-resistant seizures, as well
as treatments that prevent or impair the process of
epileptogenesis. Moreover, new therapies should particularly
include drugs with improved efficacy and tolerability, since
several of the currently available antiepileptic drugs (AEDs)
caused severe side effects (Bialer et al. 2009; Löscher and
Schmidt 2011; Simonato et al. 2014).
The mechanisms of action of AEDs are complex and in-
clude modifying the excitability of nerve by blocking of
voltage-activated sodium and/or calcium (type N, L, P/Q,
and T) channels, by influencing on GABA receptors via direct
positive allosteric modulation of GABAA receptor, or indirect-
ly, by increasing levels of GABA via inhibition of GABA
transaminase or GABA transporter. Most AEDs have multiple
pharmacological activities, whereas in case of retigabine, the
primarymechanism of action is the activation of voltage-gated
potassium channels in the brain. However, the knowledge that
is limited to the molecular targets based on binding affinity or
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biofunctional studies is insufficient to predict anticonvulsant
activity of newmolecule (Brodie et al. 2011; Rogawski 2006).
Therefore, searching for new drugs which could ameliorate
the quality of the treatment of epilepsy seems to be most
purposeful and justified. Careful pharmacological screening
of potentially suitable molecules in different groups of com-
pounds is an important part of this process. Our studies have
been focused on a group of pyrrolidine-2,5-diones as targets
for new antiepileptic drugs. Many of these compounds were
effective in animal models of seizures and displayed distinctly
better safety profile than clinically relevant AEDs
ethosuximide, lacosamide, or valproic acid (Kamiński et al.
2015a; Kamiński et al. 2015b; Obniska et al. 2015; Rybka
et al. 2014; Rybka et al. 2015). Recently, the synthesis and
evaluation of anticonvulsant activity of 22 new derivatives of
3-methylpyrrolidine-2,5-dione and pyrrolidine-2,5-dione
have been reported (Rybka et al. 2014). Five of the tested
compounds (12, 13, 15, 23, and 24) appeared to be active in
the maximal electroshock (MES) test with ED50 values range
from 16.13 to 46.07 mg/kg and two of them (12 and 23) also
in the subcutaneous pentylenetetrazole (s.c.PTZ) test with
ED50 values 134.0 and 128.8 mg/kg, respectively. Moreover,
these two compounds did not impair the motor coordination of
mice up to a dose of 500 mg/kg in the rotarod test. Thus, the
protective indices (PI) in the MES test were highly favorable
for compounds 12 (PI > 31) and 23 (PI > 13) than obtained for
reference drug: valproic acid (PI = 1.5), phenytoin (PI = 7.74),
and lacosamide (PI = 5.0), (Rybka et al. 2014; Kamiński et al.
2015a). In the s.c.PTZ test, the protective indices were also
more beneficial for compounds 12 (PI > 3.73) and 23
(PI > 3.88) than for valproic acid (PI = 1.8) and ethosuximide
(PI = 2.5).
Taking into consideration the important role of AEDs in the
treatment of neuropathic pain, studies on the search for new
AEDs should also take into account the evaluation of their
usefulness in the treatment of this type of neurological disor-
der (Mantegazza et al. 2010; Muthuraman et al. 2014). Con-
sidering the aforementioned facts, in the present study, addi-
tional experiments were performed to improve knowledge on
anticonvulsant activity of selected derivatives. Moreover,
antinociceptive activity was evaluated in two models of pain
in mice: the hot plate and the formalin tests. For preliminary
estimation of other behavioral effects, the influence on
locomotor activity of mice was also studied. Taking into
consideration that drug safety evaluation plays an impor-
tant role in the early phase of drug development, especial-
ly in the preclinical identification of biologically active
compounds, the Vibrio harveyi assay was performed to
determine mutagenic or antimutagenic properties of se-
lected derivatives. To establish the plausible mechanism
of anticonvulsant action for the most active compounds,
in vitro binding assays for sodium and L-type calcium
channels were carried out.
Materials and methods
In vivo experiments
Animals
Male CD-1 mice weighing 18–24 g were used in the in vivo
experiment. The animals were kept at room temperature of
20 ± 2 °C under standard conditions (12:12 h light-dark cycle,
standard pellet diet, tap water). All the experiments were per-
formed between 8 a.m. and 3 p.m. For the experiments, the
animals were selected in a random way and sacrificed by
cervical dislocation immediately after the assay. The experi-
mental protocol was approved by the Local Ethics Commis-
sion for Animal Experiments of the Jagiellonian University in
Cracow, and all experiences were conducted in accordance
with the 1996 NIH Guide for the Care and Use of Laboratory
Animals.
Chemicals used in pharmacological assays
The tested compounds 12 (N-[{4-(3,4-dichlorophenyl)-
piperazin-1-yl}-methyl]-3-methylpyrrolidine-2,5-dione), 13
(N-[{4-(3-trifluoromethylphenyl)-piperazin-1-yl}-methyl]-3-
methylpyrrolidine-2,5-dione), 15 (N-[{4-(3-methylphenyl)-
piperazin-1-yl}-methyl]-3-methylpyrrolidine-2,5-dione), 23
(N-[{4-(3,4-dichlorophenyl)-piperazin-1-yl}-methyl]-pyrrol-
idine-2,5-dione), and 24 (N-[{4-(3-trifluoromethylphenyl)-
piperazin-1-yl}-methyl]-pyrrolidine-2,5-dione) were synthe-
sized at the Department of Medicinal Chemistry, Jagiellonian
University Medical College in Cracow (Scheme 1). The syn-
thesis of the investigated compounds was described earlier
(Rybka et al. 2014). The investigated compounds were
suspended in a 0.5 % aqueous solution of methylcellu-
lose (Loba Chemie, Germany). Lacosamide (Vimpat,
UCB Pharma, Belgium), pilocarpine (Sigma-Aldrich,
Germany), scopolamine butylbromide (Sigma-Aldrich,
Germany), and formaldehyde (POCh, Poland) were dis-
solved in distilled water. Agents were administered intra-
peritoneally (i.p.) at a volume of 0.1 ml/10 g. Control
animals were administered an equivalent volume of ve-
hicle (0.5 % aqueous solution of methylcellulose) via the
same route as the test compounds. The tested compounds
were administered 4 h before the experiments, and
lacosamide was administered 30 min before the tests (at
the previously established time of peak drug effect). The
pretreatment times and doses of tested compounds and
lacosamide were established based on previous studies,
as well as information about the biological activity of
lacosamide taken from the literature (Kamiński et al.
2015a; Rybka et al. 2014; Stöhr et al. 2006; Stöhr
et al. 2007).
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Electroconvulsive threshold test (maximal electroshock
seizure threshold test; MEST test)
Electroconvulsions were produced by alternating current (du-
ration of the stimulus 0.2 s; 50 Hz) delivered via auricular
electrodes by an electroshock generator (Rodent Shocker,
Type 221, Hugo Sachs, Germany) according to the procedure
described elsewhere (Löscher et al. 1991; Sałat et al. 2012).
Full tonic extension of both hind limbs was taken as the end-
point. Mice not displaying hind limb tonic extension were
considered protected from seizure. The convulsive threshold
was evaluated as CS50, defined as current strength (in mA)
required to induce tonic hind limb extension in 50 % of the
animals tested, using log-probit method (Litchfield and
Wilcoxon 1949). For the evaluation of electroconvulsive
threshold, at least three groups of mice (6–8 animals per
group) were used.
Pilocarpine-induced seizure test
The experimental procedure was originally described by
Turski et al. (1987). Seizures were induced in mice by i.p.
injection of pilocarpine at a dose of 400 mg/kg. Forty-five
minutes before pilocarpine, animals were also pretreated with
scopolamine butylbromide (1 mg/kg, i.p.) to reduce peripheral
autonomic side effects and masticatory and stereotyped move-
ments (Kowalczyk et al. 2014). Direct observation was per-
formed for 60 min to monitor the latency time to the onset of
the limbic seizures, characterized by a subsequent develop-
ment of behavioral symptoms, such as tremor, head bobbing,
and myoclonic movements of the forelimbs progressing to
recurrent myoclonic convulsions with rearing, salivation, fall-
ing, and status epilepticus (Łuszczki et al. 2008; Turski 2000).
The hot plate test
In the hot plate test, the mice were i.p. pretreated either with
the test compound or vehicle before placing the animal on the
hot plate apparatus (Panlab/Harvard Apparatus, Spain). This
apparatus has an electrically heated surface and is supplied
with a temperature controller that maintains the temperature
at 55–56 °C. The time to the first reaction (licking or jumping)
of mice to a nociceptive stimulus was recorded. The cutoff
time was established to 60 s to avoid paw tissue damage (Sałat
et al. 2014).
The formalin test
Antinociceptive activity in the formalin hind paw test was
examined according to Laughlin et al. (2002). Twenty micro-
liters of a 5 % formalin solution was injected intraplantarly
(i.pl.) into the right hind paw of the mouse. Immediately after
formalin injection, the animals were placed individually into
glass beakers and were observed for the next 30 min. Time (in
seconds) spent on licking or biting the injected hind paw in
selected intervals, 0–5 and 15–30 min, was measured in each
experimental group and was an indicator of nociceptive be-
havior. In mice, intraplantarly injection of diluted formalin
produces a biphasic nocifensive behavioral response (i.e.,
licking or biting the injected hind paw). The acute nociceptive
phase lasts for the first 5 min, whereas the second inflamma-
tory phase occurs between 15 and 30 min after formalin
injection.
Spontaneous locomotor activity
Locomotor activity was measured with photoresistor
actometers (Ugo Basile, Italy) connected to a counter for the
recording of light-beam interruptions. Mice were individually
placed in plastic cages for 30 min habituation period, and then
the number of light-beam crossings was counted for a 30-min
session. The cages were cleaned up with 70 % ethanol after
each mouse.
In vitro experiments
Two V. harveyi strains were used in the experiments: wild-type
BB7 and genetical ly modified BB7XM (the UV-
hypersensitive strain bearing plasmid pAB91273), which
were described previously by Czyż et al. (2000). The standard
mutagen used as a positive control was 4-nitroquinoline-
R R1
12 CH3 3,4-diCl
13 CH3 3-CF3
15 CH3 3-Cl
23 H 3,4-diCl
24 H 3-CF3
Scheme 1 Schematic structure of the studied pyrrolidine-2,5-dione and
3-methylpyrrolidine-2,5-dione
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N-oxide (NQNO). The final concentration of NQNO solution
used in the tests was 40 ng/ml.
Mutagenicity assayMutagenicity assay was performed as de-
scribed previously (Czyż et al. 2000). All experiments were
carried out in triplicate and the results were expressed as muta-
genic index (M.I. = the number of revertant colonies induced in
the tested sample/the number of spontaneous revertants in the
negative control) (Gulluce et al. 2010). A compound was con-
sidered mutagenic when the M.I. was equal or greater than 2.
Antimutagenicity assay Antimutagenicity assay was per-
formed according to previously described procedures (Czyż
et al. 2002; Pękala et al. 2013). All experiments were analyzed
in three independent repetitions and the results were expressed
as percent inhibition (the ability of the compounds to inhibit
the action of NQNO). This was calculated as follows: Inhibi-
tion (%) = 100 − [(R1/R2) × 100], where R1 is the number of
revertants per plate induced by test compound plus mutagen
and R2 is the number of revertants in the plate containing only
the mutagen (Słoczyńska et al. 2010). No antimutagenic effect
was considered when the inhibition was less than 25 %; a
moderate effect for an inhibition value between 25 and 40 %
and a strong antimutagenicity were recorded for inhibition
higher than 40 % (Gulluce et al. 2010).
Sodium and calcium channels binding studies
The radioligand binding studies were performed commercial-
ly by Cerep (Celle I’Evescault, France). The binding assays
for sodium channel (site 2) was performed using the
[3H]batrachotoxin and for L-type calcium channel using
[3H]nitrendipine as radioligands. Compound binding was
expressed as a percentage of inhibition of the binding of a
radioactively labeled ligand.
Statistics
The log-probit method described by Litchfield and Wilcoxon
(1949) was used to establish a median current strength (CS50)
value with the 95 % confidence limits. All the data are pre-
sented as the mean ± SEM. Results were statistically evaluated
using Student’s t test or the one-way analysis of variance
(ANOVA) followed by Dunnett’s post hoc comparison test.
P < 0.05 was considered statistically significant.
Results
Influence on the seizure threshold in the MEST test
At a dose of 30 mg/kg, all test compounds caused elevated
electroconvulsive threshold (ECT) in comparison to vehicle-
treated mice. At this dose, the highest activity revealed com-
pounds 12 and 24, which increased ECT by 118 % (p < 0.01)
and 114 % (p < 0.001), respectively. The other agents were
able to elevate ECT by 24–61 %. At a dose of 10 mg/kg,
compounds 12 and 24 increased ECT by 51 % (p < 0.001)
and 68 % (p < 0.001), respectively. Significant activity re-
vealed also compound 23, since it increased threshold by
61 % (p < 0.0001) at a dose of 30 mg/kg and by 27 %
(p < 0.01) at a dose of 10 mg/kg. Reference drug lacosamide
at a dose of 10 mg/kg proved to be highly effective in electri-
cally induced seizures, since it increased threshold for
electroconvulsions above 25 mA (Table 1).
Anticonvulsant activity in the pilocarpine-induced seizure
test
At a dose of 100 mg/kg, two compounds, 12 and 23, in a
statistically significant manner prolonged the latency time to
seizures by 37 % (p < 0.05) and by 95 % (p < 0.001), respec-
tively. Lacosamide at a dose of 40 mg/kg, which was the
highest dose without neurotoxic effects in mice, also revealed
antiseizure activity, since it prolonged latency time to seizures
by 50 % (p < 0.05) (Table 2).
Antinociceptive activity in the hot plate test
A significant antinociceptive activity was observed for four of
the test compounds: 12, 13, 15, and 24. Only compound 23
did not show activity in the test. The greatest effect possessed
compound 13, which at a dose of 30 mg/kg significantly
prolonged the latency time to pain reaction from
27.51 ± 1.36 s (vehicle-treated group) to 56.03 ± 1.75 s (by
104 %, p < 0.0001). Also compounds 15 and 24 displayed a
potent effect, as they significantly prolonged the latency time
to pain reaction from 27.51 ± 1.36 to 47.12 ± 6.14 s (by 71 %,
p < 0. 01) and 47.23 ± 3.77 s (by 72 %, p < 0.0001), respec-
tively. Compound 12 prolonged the latency time to pain reac-
tion to 39.73 ± 3.20 s (by 44 %, p < 0.01). The results are
presented in Fig. 1.
Antinociceptive activity in the formalin hind paw test
The formalin test was used as a tonic model of nociception. A
significant antinociceptive activity was observed for each of
the test compounds, given at a dose of 30 mg/kg. In the first
(neurogenic) phase of the test, four of the tested compounds
significantly reduced the duration of the licking response by
39 % (p < 0.05)—12, 79 % (p < 0.001)—13, 52 %
(p < 0.01)—15, and 62 % (p < 0.001)—24. Only compound
23 did not attenuate the nocifensive response in this phase in a
statistically significant manner. In the same phase, lacosamide
at a dose of 30 mg/kg displayed antinociceptive effect, as it
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significantly decreased the duration of the licking response by
69 % (p < 0.001) (Fig. 2).
In the second (late) phase of the formalin test, a prominent
statistically significant antinociceptive effect was observed for
all compounds: 12 (74 %, p < 0.001), 13 (89 %, p < 0.0001),
15 (66 %, p < 0.001), 23 (89 %, p < 0.0001), 24 (94 %,
p < 0.0001), and lacosamide (90 %, p < 0.0001) (Fig. 2).
Influence on locomotor activity
Only compound 12 given at a fixed dose of 30 mg/kg did not
significantly influence on locomotor activity in mice, while
four of the test compounds, 13 (p < 0.0001), 15
(p < 0.0001), 23 (p < 0.01), and 24 (p < 0.0001), significantly
reduced the number of crossings registered with photoresistor
actometers. Also, in the case of lacosamide, a significant
decrease of locomotor activity was observed at a dose of
30mg/kg (p < 0.001). The precise data are illustrated in Fig. 3.
Mutagenic and antimutagenic activity
In the present study, the V. harveyi assay was used to evaluate
mutagenic and antimutagenic properties of four new
Table 1 Effect of the tested and reference compounds on the
electroconvulsive threshold
Cmpd Dose (mg/kg) CS50 (mA) (CI) SE
Vehicle – 6.53 (6.11–6.99) 0.22
12 30 14.27 (8.21–24.80)** 2.56
13 30 9.37 (5.47–16.07)* 1.60
15 30 8.11 (7.12–9.24)*** 0.43
23 30 10.53 (8.06–13.77)**** 0.91
24 30 14.01 (9.05–21.70)*** 2.24
Vehicle – 5.27 (4.35–6.37) 0.33
12 10 7.94 (6.57–9.57)*** 0.50
Vehicle – 6.61 (6.38–6.85) 0.23
23 10 8.42 (7.55–9.39)** 0.39
24 10 11.11 (8.12–15.20)*** 1.27
Lacosamide 10 >25 –
CI confidence interval, SE standard errors
Data analyzed by log-probit method according to Litchfield and
Wilcoxon. Result presented as median current strengths (CS50) required
to evoke tonic hind limb extension in 50 % of mice tested. The com-
pounds were administered i.p. 4 h before the test. Lacosamide was ad-
ministered i.p. 30 min, before the test
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs vehicle; N = 18–
24
Table 2 Anticonvulsant activity
of the tested and reference
compounds in pilocarpine-
induced seizures model
Cmpd Dose Latency to status epilepticus (s) ± SEM Anticonvulsant effect (%)
Vehicle – 342.6 ± 38.15 –
12 100 468.8 ± 39.60* 36.8
13 100 296.7 ± 9.63 –
15 100 406.0 ± 59.77 18.5
23 30 465.8 ± 37.61 36.8
100 669.4 ± 73.04*** 95.4
24 100 346.7 ± 25.92 1.2
Vehicle 338.8 ± 37.85 –
Lacosamide 30 382.1 ± 22.86 12.8
40a 507.7 ± 52.11* 49.8
Each value represents the mean ± SEM obtained from 6 to 8 mice. Anticonvulsant activity compared to vehicle-
treated mice. Statistical analysis: Student’s t test (12, 13, 15, and 24) and one-way analysis of variance (ANOVA),
followed by Dunnett’s post hoc test (23 and lacosamide): F [2, 19] = 15.72, p < 0.001 (23); F [2, 18] = 4.995,
p < 0.05 (lacosamide). The compounds were administered i.p. 4 h; lacosamide was administered i.p. 30 min
before pilocarpine
*p < 0.05, **p < 0.01, ***p < 0.001 vs vehicle; N = 6–8
a The highest dose of lacosamide without neurotoxic effects in mice
Fig. 1 Effects of compounds 12, 13, 15, 23, 24, and lacosamide at the
dose of 30 mg/kg on response latency in the hot plate test in mice. Data
are presented as mean ± SEM and were analyzed by Student t test.
Significant difference compared to the vehicle-treated group—
**p < 0.01, ****p < 0.0001; N = 8–10
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derivatives of pyrrolidine-2,5-dione (12, 13, 23, and 24). The
results of the V. harveyi mutagenicity and antimutagenicity
assays for selected derivatives of pyrrolidine-2,5-dione were
depicted in Table 3. We found that all tested compounds at a
concentration of 40 ng/ml had no mutagenic activity in V.
harveyi BB7 and BB7XM strains. The obtained results show
that compound 13 was the most active antimutagenic agent
tested. It is worth noting, that compound 13 displayed the
highest values of inhibition rates of mutagenicity in all bacte-
rial strains used in the experiment. Two of the compounds
investigated, i.e., 12 and 13, were moderate inhibitors of the
mutagenicity induced by the direct-acting mutagen NQNO in
V. harveyi BB7 strain. The inhibition percentages of these
substances ranged from 26 to 35, whereas compounds 23
and 24 weakly suppressed the mutagenicity of NQNO in V.
harveyi BB7 strain. The inhibition rates for this compound
ranged between 15 and 18 %. Summing up, the most benefi-
cial antimutagenic properties showed compound 13, which
exhibited relatively moderate antimutagenic properties in all
tested strains.
In vitro sodium and calcium channel binding studies
Two compounds 12 and 23which showed prominent anticon-
vulsant activity and the highest protective indices (PI
MES = 31 and 13, respectively) were examined in the binding
studies. According to the method applied, compound binding
was calculated as a % inhibition of the binding of a radioac-
tively labeled ligand specific for each target. The results are
shown in Tables 4 and 5. The tested compounds at a concen-
tration of 100 μM revealed high inhibition of Na+ channel
(site 2), as it is indicated by inhibition greater than 50 %. At
a concentration of 10 μM, these derivatives revealed moderate
activity (compound 12—49.1 % and compound 23—49.4 %)
(Table 4). It should be highlighted that compounds 12 and 23
were stronger Na+ channel blockers than phenytoin and car-
bamazepine, which are known to be the anticonvulsants that
act as sodium channel blockers.
Moreover, both compounds 12 and 23 were observed as
relatively effective binders to L-type calcium channels at a
concentration of 100 μM, as they showed inhibition higher
than 50 %—compound 12 blocked calcium channels in
59.4 % while compound 23 in 65.9 %. Reduction of the con-
centration to 10 μM resulted in a significant decrease in inter-
action of compounds with voltage-gated L-type calcium chan-
nel—compound 12 blocked this channel in 20.2 % whereas
compound 23 in 12.3 % (Table 5). The results of the tested
compounds are similar to those obtained for phenytoin.
Topiramate, which is the novel AED with a broad therapeutic
spectrum, at a concentration of 100 μM was a much weaker
binder to the L-type calcium channel than the tested com-
pounds. The findings from the binding studies suggest that
the mechanism of anticonvulsant action of compounds is
Fig. 2 Effects of compounds 12, 13, 15, 23, 24, and lacosamide at the
dose of 30 mg/kg on the duration of the licking response in a the early
(neurogenic) phase (0–5 min) or b the late (inflammatory) phase (15–
30 min) of the formalin test. Data are presented as mean ± SEM and were
analyzed by Student t test. Significant difference compared to the vehicle-
treated group: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001;
N = 8–10
Fig. 3 Effects of compounds 12, 13, 15, 23, 24, and lacosamide at the
dose of 30 mg/kg on locomotor activity in mice. Data are presented as
mean ± SEM of beam breaks recorded for 30 min (n = 6–10). Statistical
analysis of the results was conducted using Student t test. Significant
difference compared to the vehicle-treated group: **p < 0.01,
***p < 0.001, ****p < 0.0001; N = 6–10
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connected with the inhibition of sodium and calcium voltage-
gated channels. It is notably visible at a concentration of
100 μM, since compounds 12 and 23 showed binding to both
sodium and calcium channels higher than in 50 %.
Discussion
In this paper, extended studies regarding anticonvulsant and
antinociceptive activities of new pyrrolidine-2,5-dione and 3-
methylpyrrolidine-2,5-dione are demonstrated. Here, we
show that all tested compounds at the dose of 30 mg/kg were
able to increase the seizure threshold in the electroconvulsive
threshold test. This test, as well as maximal electroshock sei-
zure model (MES test), is regarded to be an experimental
model of tonic-clonic seizures and, to a certain extent, partial
convulsions with or without secondary generalization in
humans (Löscher et al. 1991). Furthermore, the electroconvul-
sive threshold test can be useful for detecting anticonvulsant
agents that act as voltage-gated sodium channel blockers. In
the aforementioned experiment, compounds 12, 23, and 24
were the most active, as they most considerably elevated the
threshold for electroconvulsions in mice, which confirms their
excellent anticonvulsant activity in the electrically induced
seizures. It is worth noting that the threshold for
electroconvulsions in mice seems to be more sensitive than
traditional maximal electroshock-induced seizure test as
regards the detection of the anticonvulsant properties of anti-
epileptic drugs (Łuszczki et al. 2007).
The pilocarpine-induced seizure model of epilepsy, origi-
nally described by Turski et al. (1987). is a rodent model of
status epilepticus. In this test, anticonvulsant drugs including
Table 3 Mutagenicity and
antimutagenicity of derivatives of
the tested compounds in the
Vibrio harveyi test
Cmpd Mutagenicity Antimutagenicity
BB7a BB7XMa BB7a BB7XMa
Mean ± SD M.I.c Mean ± SD M.I.c Mean ± SD Inhib.
(%)d
Mean ± SD Inhib.
(%)d
DMSOb 16 ± 3 12 ± 4 17 ± 2 15 ± 3
NQNOb 32 ± 4 2.0 24 ± 3 2.1 38 ± 5 24 ± 4
12 25 ± 4 1.5 14 ± 6 1.2 28 ± 4 (26) 23 ± 5 (5)
13 22 ± 3 1.4 20 ± 5 1.7 25 ± 4 (35) 20 ± 4 (16)
23 19 ± 2 1.2 9 ± 3 0.7 32 ± 3 (15) 24 ± 2 (1)
24 25 ± 4 1.6 19 ± 1 1.6 31 ± 5 (18) 29 ± 3 (0)
a Number of revertants; b NQNO (nitroquinoline-N-oxide, 40 ng/ml) was used as positive control; DMSO was
used as negative control; cM.I. (mutagenic index): number of induced revertants/number of spontaneous rever-
tants (positive assay when M.I. ≥ 2); d The values in parenthesis are the inhibition rates (%) of mutagenicity; 25–
40 % inhibition: moderate antigenotoxicity, 40 % or more inhibition: strong antigenotoxicity, 25 % or less
inhibition: no antigenotoxicity
Table 4 In vitro Na+ channel
(site 2) binding assays Cmpd Concentration (μM) % inhibition of control specific binding
12 10 49.1
100 85.8
23 10 49.4
100 89.9
Phenytoina 10 10.6
100 21.2
Carbamazepineb 10 4.6
100 17.4
Compounds were each evaluated in preparations from rat cerebral cortex as inhibitors of the specific binding of
[3 H]batrachotoxin to the voltage-sensitive sodium channel. Results showing an inhibition higher than 50 % are
considered to represent significant effects of the test compounds; results showing an inhibition between 25 and
50 % are indicative of moderate effect; results showing an inhibition lower than 25 % are not considered
significant
a Data from the previous study (Rybka et al. 2015)
b Data from the previous study (Kamiński et al. 2015b)
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diazepam, clonazepam, valproic acid, and phenobarbital pre-
vent pilocarpine-induced convulsions (Łuszczki et al. 2008).
In the previous study, tested compounds proved to be more
active in electrically induced (MES test) than in chemically
induced seizures (s.c.PTZ test). Therefore, in the pilocarpine-
induced seizures, tested compounds were examined at a fixed
dose of 100 mg/kg. The significant activity displayed only
two compounds: 12 and 23. These compounds were also ac-
tive in electrically induced seizures and pentylenetetrazole-
induced seizures (previous study); therefore, they seem to be
molecules which display broad spectra of anticonvulsant ef-
fects. Lacosamide, a novel anticonvulsant drug tested at a dose
of 40 mg/kg (the highest dose that did not cause neurotoxic
effects in mice), also significantly prolonged latency time to
status epilepticus in aforementioned animal model of seizures.
Currently this drug, as well as other second-line drugs, such as
levetiracetam, topiramate, or pregabaline have been increas-
ingly used for the treatment of status epilepticus in humans
(Kellinghaus et al. 2014; Rossetti and Lowenstein 2011).
It is well known that antiepileptic drugs (AEDs) are used
not only to treat epilepsy but also to treat diverse non-epileptic
conditions, including pain (neuropathic pain, migraine pro-
phylaxis), neuromuscular disorders, and psychiatric disorders
(anxiety, bipolar affective disorders) (Mantegazza et al. 2010;
Rogawski and Löscher 2004). Studies by various groups
using different models of pain suggest that antiepileptic drugs
can inhibit sensitized signaling associated with allodynia and
hyperalgesia (Beyreuther et al. 2006; Laughlin et al. 2002;
Sałat et al. 2014).
Therefore, the objective of this study was also to character-
ize the antinociceptive activity of the tested compounds. This
activity was investigated in mice in the hot plate test and the
formalin test. The hot plate test is widely used for evaluation
of the centrally acting analgesics. The mechanism of analgesic
effect observed here is found to be a consequence of
supraspinal attenuation of ascending nociceptive input
(Listos et al. 2014; Manzanares et al. 2006). In the present
study, four of the tested compounds, 12, 13, 15, and 24, as
well as lacosamide at a dose of 30 mg/kg, significantly
prolonged the latency time for reaction responses. The highest
activity showed compound 13, which prolonged the latency
time to pain reaction by about 104 %.
Many studies have demonstrated that compounds which
revealed anticonvulsant activity in the MES test exhibit an
antinociceptive action in the formalin test in mice. The injec-
tion of formalin to a mouse paw which results in neuronal
damage produced two phases of pain response: the early–
acute chemical pain and the late–tonic nociception involving
central sensitization (Laughlin et al. 2002). It has been report-
ed that the late phase is either the effect of sensitization of the
dorsal horn neurons of the spinal cord or inflammation-
induced hyperactivity of afferent nociceptors or combination
of both (Ximenes et al. 2013). For compounds 12, 13, 15, and
24, as well as lacosamide at the dose of 30 mg/kg, the signif-
icant analgesic effect was observed in the early (neurogenic)
phase of the test. Whereas compound 23, likewise in the hot
plate test, did not reveal significant analgesic activity in the
first phase. In this phase of formalin test, likewise in the hot
plate test, the most active was compound 13. These results
indicate that this compound exerts a prominent central
antinociceptive effect. In the second phase of the formalin test,
all of tested compounds, as well as lacosamide, revealed a
significant antinociceptive activity. Lacosamide displayed an
analgesic effect in this test also in research conducted by other
groups (Beyreuther et al. 2007; Stöhr et al. 2006).
The obtained results of anticonvulsant and antinociceptive
activity are very promising. However, compounds 13, 15, 23,
and 24 significantly altered the locomotor activity of mice;
thus, drug-induced sedation can impede the use of these com-
pounds as potential drugs. Hence, compound 12, with remark-
able anticonvulsant and antinociceptive properties, which did
not produce any significant effects on the locomotor activity,
as well as the motor coordination in rotarod test (even at high
doses TD50 > 500 mg/kg), seems to be the most promising
Table 5 In vitro L-type Ca+
(dihydropyridine site) channel
binding assays
Cmpd Concentration (μM) % inhibition of control specific binding
12 10 20.2
100 59.4
23 10 12.3
100 65.9
Phenytoin 10 6.6
100 57.8
Topiramatea 100 7.9
Compounds were each evaluated in preparations from rat cerebral cortex as inhibitors of the specific binding of
[3 H]nitrendipine to the L-type calcium channel. Results showing an inhibition higher than 50% are considered to
represent significant effects of the test compounds; results showing an inhibition between 25 % and 50 % are
indicative of moderate effect; results showing an inhibition lower than 25 % are not considered significant
a Data from the previous study (Kamiński et al. 2015b)
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compound, thus prompting further studies to confirm its safety
and efficacy.
In the V. harveyi assay, the studied agents did not display
mutagenic activity. It is noteworthy that in the case of deriva-
tive 13, its antimutagenic activity against 4-NQO implies that
this compound may directly protect against DNA damage
from mutagens. Additionally, it appears that the V. harveyi
assay can be applied for primary mutagenicity and
antimutagenicity assessment of chemical substances, thus
representing a useful alternative tool for compound safety
evaluation.
In spite of intensive research on the physiological and bio-
chemical bases of epilepsy, its pathogenesis is not completely
understood; however, it is known that the cause of seizures
can be malfunctioning of both sodium and calcium channels.
The voltage-gated sodium channels have been the target of
many antiepileptic drugs, including phenytoin, lamotrigine,
and carbamazepine. Moreover, lacosamide has been found
also as a voltage-gated sodium channel inhibitor, but it differs
from other AEDs in the fact that it selectively enhances the
slow inactivation without affecting the fast inactivation of
these channels (Perucca et al. 2007). Like other voltage-
gated ion channels, voltage-gated Ca2+ (L-, P/Q-, N-type)
channels play an essential role in proper functioning of neu-
rons. The well-known AEDs which influence L-type calcium
channel activity are phenytoin, topiramate, and felbamate
(Liu et al. 2003; Rogawski and Löscher 2004). Taking into
account the above remarks, the influence on the neuronal
voltage-sensitive sodium and L-type calcium channels was
determinated for two compounds, 12 and 23, which showed
prominent anticonvulsant activity with high protective indi-
ces. At a concentration of 100 μM, these selected active
molecules inhibited sodium and calcium voltage-gated chan-
nels in highly more than 50 %, which is a better result than
for the reference drugs—phenytoin, carbamazepine, and
topiramate. At a concentration of 10 μM, they still revealed
a moderate effect on sodium and calcium channels. It should
be highlighted that derivatives 12 and 23 were stronger
sodium (site 2) and L-type calcium channel blockers than
reference drugs.
Conclusions
In conclusion, we demonstrated by several in vivo experimen-
tal models prominent anticonvulsant and analgesic effects of
new derivat ives of pyrrol idine-2,5-dione and 3-
methylpyrrolidine-2,5-dione. The most promising effect was
observed for compounds 12 and 23 which displayed broad
spectra of anticonvulsant activity. At active doses in experi-
mental tests, compound 12 did not show sedative properties.
Moreover, the tested molecules did not display mutagenic
activity in the V. harveyi assay. The in vitro binding study
indicated that the plausible mechanism of action of com-
pounds 12 and 23 was the influence on the neuronal
voltage-sensitive sodium (site 2) and L-type calcium channels.
The results obtained in the current studies proved that in the
group of pyrrolidine-2,5-diones, new anticonvulsants with
collateral analgesic properties can be found.
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